Mantle Cell Lymphoma ' Pipeline Review, H1 2013

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Mantle Cell Lymphoma ' Pipeline Review, H1 2013
Published on February 2013

Report Summary


Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Mantle Cell Lymphoma, complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Mantle Cell Lymphoma. Mantle Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Mantle Cell Lymphoma.
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Mantle Cell Lymphoma ' Pipeline Review, H1 2013 (From Slideshare) Page 1/8


Table of Content

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mantle Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Mantle Cell Lymphoma 10
Mantle Cell Lymphoma Therapeutics under Development by Companies 12
Mantle Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Early Clinical Stage Products 19
Discovery and Pre-Clinical Stage Products 20
Mantle Cell Lymphoma Therapeutics ' Products under Development by Companies 21
Mantle Cell Lymphoma Therapeutics ' Products under Investigation by Universities/Institutes 23
Companies Involved in Mantle Cell Lymphoma Therapeutics Development 25
Amgen Inc. 25
Sanofi-Aventis 26
GlaxoSmithKline plc 27
Gilead Sciences, Inc. 28
Infinity Pharmaceuticals, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Pfizer Inc. 32
SuperGen, Inc. 33
Cell Therapeutics, Inc. 34
Celgene Corporation 35
Celldex Therapeutics, Inc. 36
Accentia Biopharmaceuticals, Inc. 37
Telik, Inc. 38
Pharmacyclics, Inc. 39
Memgen, LLC. 40
Semafore Pharmaceuticals, Inc. 41
Stemline Therapeutics, Inc. 42
Onconova Therapeutics, Inc 43
Cylene Pharmaceuticals, Inc. 44
Cancer Therapeutics CRC Pty Ltd 45



Advancell 46
Mantle Cell Lymphoma ' Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Drug Profiles 49
navitoclax - Drug Profile 49
pacritinib - Drug Profile 51
CDX-1127 - Drug Profile 53
acadesine - Drug Profile 54
ibrutinib - Drug Profile 56
abexinostat hydrochloride - Drug Profile 60
SAR-245409 - Drug Profile 62
panobinostat - Drug Profile 64
BiovaxID - Drug Profile 67
AT-7519 - Drug Profile 69
bortezomib - Drug Profile 71
idelalisib - Drug Profile 75
ISF-35 - Drug Profile 77
canfosfamide hydrochloride - Drug Profile 79
SF-1126 - Drug Profile 83
SL-101 - Drug Profile 85
ON-013105 - Drug Profile 86
P-276 - Drug Profile 87
P-1446 - Drug Profile 89
belinostat + [bortezomib] - Drug Profile 91
bortezomib + [rituximab] - Drug Profile 92
bortezomib + vorinostat - Drug Profile 93
Therapeutic allogeneic lymphocytes program - Drug Profile 94
buparlisib - Drug Profile 95
PD-0332991 - Drug Profile 98
lenalidomide - Drug Profile 100
lenalidomide - Drug Profile 103
iodine-131 anti-B1 antibody + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 106
etoposide + [cyclophosphamide] + [rituximab] + Radioimmunotherapy - Drug Profile 108
PD-0332991 + [bortezomib] - Drug Profile 110
cytarabine + doxorubicin + Radioimmunotherapy - Drug Profile 111
IPI-145 - Drug Profile 113
Other Developmental Activities 114
CX-5461 - Drug Profile 115
Research and Development Brief 115
Discovery/Preclinical Trial Details 115
ibritumomab tiuxetan + [rituximab] - Drug Profile 117
Phase II - Trial Details 117
ABT-199 - Drug Profile 119
SAR-245409 + [rituximab] - Drug Profile 120



Phase I - Trial Details 120
SAR-245409 + [bendamustine hydrochloride] + [rituximab] - Drug Profile 121
SAR-245409 + [bendamustine hydrochloride] - Drug Profile 122
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 123
Drug Targeting PRMT5 - Drug Profile 124
ATRA For Mantle Cell Lymphoma - Drug Profile 126
Discovery/Preclinical Trial Details 126
131I-Rituximab - Drug Profile 127
Rituximab + Cytarabine + Dexamethasone + Bortezomib - Drug Profile 128
Belinostat + [Rituximab] + [Zevalin] - Drug Profile 130
Phase II - Trial Details 130
alisertib + [bortezomib] + [rituximab] - Drug Profile 131
Andrographolide - Drug Profile 132
Mantle Cell Lymphoma Therapeutics ' Drug Profile Updates 133
Mantle Cell Lymphoma Therapeutics ' Discontinued Products 164
Mantle Cell Lymphoma Therapeutics - Dormant Products 165
Mantle Cell Lymphoma ' Product Development Milestones 167
Featured News & Press Releases 167
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174

List of Tables

Number of Products Under Development for Mantle Cell Lymphoma, H1 2013 13
Products under Development for Mantle Cell Lymphoma ' Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 19



Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 27
Amgen Inc., H1 2013 28
Sanofi-Aventis, H1 2013 29
GlaxoSmithKline plc, H1 2013 30
Gilead Sciences, Inc., H1 2013 31
Infinity Pharmaceuticals, Inc., H1 2013 32
Millennium Pharmaceuticals, Inc., H1 2013 33
Novartis AG, H1 2013 34
Pfizer Inc., H1 2013 35
SuperGen, Inc., H1 2013 36
Cell Therapeutics, Inc., H1 2013 37
Celgene Corporation, H1 2013 38
Celldex Therapeutics, Inc., H1 2013 39
Accentia Biopharmaceuticals, Inc., H1 2013 40
Telik, Inc., H1 2013 41
Pharmacyclics, Inc., H1 2013 42
Memgen, LLC., H1 2013 43
Semafore Pharmaceuticals, Inc., H1 2013 44
Stemline Therapeutics, Inc., H1 2013 45
Onconova Therapeutics, Inc, H1 2013 46
Cylene Pharmaceuticals, Inc., H1 2013 47
Cancer Therapeutics CRC Pty Ltd, H1 2013 48
Advancell, H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Mantle Cell Lymphoma Therapeutics ' Drug Profile Updates 136
Mantle Cell Lymphoma Therapeutics ' Discontinued Products 167
Mantle Cell Lymphoma Therapeutics ' Dormant Products 168
Mantle Cell Lymphoma Therapeutics ' Dormant Products (Contd..1) 169

List of Figures

Number of Products under Development for Mantle Cell Lymphoma, H1 2013 13
Products under Development for Mantle Cell Lymphoma ' Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22



Discovery and Pre-Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Mantle Cell Lymphoma ' Pipeline Review, H1 2013

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Mantle Cell Lymphoma ' Pipeline Review, H1 2013